Recombinant Rhesus Macaque JAK2 Protein, His (Fc)-Avi-tagged
Cat.No. : | JAK2-2148R |
Product Overview : | Recombinant Rhesus Macaque JAK2 with His (Fc)-Avi tag was expressed and purified |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Rhesus Macaque |
Tag : | His&Fc&Avi |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method |
Purity : | ≥85% by SDS-PAGE |
Stability : | Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
Storage : | For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Storage Buffer : | PBS buffer |
Gene Name : | JAK2 Janus kinase 2 [ Macaca mulatta (Rhesus monkey) ] |
Official Symbol : | JAK2 |
Synonyms : | JAK2; tyrosine-protein kinase JAK2; |
Gene ID : | 694184 |
mRNA Refseq : | NM_001265901 |
Protein Refseq : | NP_001252830 |
UniProt ID : | F7GT47 |
Products Types
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewQuick response from customer service.
Product performed as expected.
Satisfied with product quality.
Q&As (7)
Ask a questionJAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.
Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.
JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.
JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.
JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.
Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.
Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).
Ask a Question for All JAK2 Products
Required fields are marked with *
My Review for All JAK2 Products
Required fields are marked with *
Inquiry Basket